Three interconnected capabilities that compound value at every level: for clinic owners, for patients, and for investors.
GLV targets independently owned metabolic health clinics, med spas, and hormone therapy practices across the United States. We look for established operations with loyal patient bases and real untapped revenue. Not turnarounds.
Our acquisition model is designed to preserve what clinic owners built while unlocking the revenue and scale they couldn't access alone.
Golden Lotus Labs is GLV's proprietary supply chain. It's our structural moat. Every clinic we acquire gets integrated into the Labs supply chain, capturing margin on both sides of the transaction. No external acquirer can replicate this quickly.
The Labs supply chain transforms an acquired clinic's cost structure within 60–90 days of integration. Better products. Better margins. Faster access to new therapeutic categories as they emerge.
We deploy a proprietary AI platform across every acquired clinic. This isn't off-the-shelf software. It's purpose-built for metabolic health practice management.
The result: clinic owners get the operational support a PE-backed platform would charge a premium for, without giving up control of what they built.
The GLV model runs on a specific, repeatable cycle: acquisition, integration, exit. The supply chain and AI layer are what makes the math work.
Acquire established independent clinics. Integrate our supply chain and AI platform. Build the kind of scale no independent can create alone. Exit at a multiple that reflects a real infrastructure business, not a single isolated practice.
Unlike purely financial buyers, GLV brings compounding advantages that take years to replicate.
Golden Lotus Labs is a functioning operation built to FDA guidelines. Not a future plan. Margin is captured on both sides of every transaction.
We evaluate peptide mix, GLP-1 pipelines, and adjacent service potential. We find value in practices that look ordinary to a financial buyer.
The AI operational layer is built and tested on real clinic operations. Not a whitepaper. It deploys within 60 days of acquisition close.
20+ years inside health businesses, biotech, and Fortune 100 consulting. We know where the value hides and where the margin leaks.
Whether you're a clinic owner evaluating your options or an investor building a healthcare thesis, we'd like to talk.